In this article
Cross-Border Journey: From Rhabdomyosarcoma Diagnosis to Proton Therapy
In September 2015, a child patient with rhabdomyosarcoma in Guangdong, China successfully completed proton radiotherapy at the Proton Center of the Eastern Hospital of the National Cancer Center in Japan.
The family members of the children took photos with the doctors and nurses of proton radiotherapy to celebrate the successful completion of the treatment. When the little patient was seen on November 23, 2014, he had already experienced abdominal pain for half a month, and had a fever for four days. . The results of the biopsy on November 27 were considered embryonic rhabdomyosarcoma. Stage 4 chemotherapy was performed from December 1, 2014 to February 4, 2015, and surgery was performed on April 10, 2015. Postoperative pathological diagnosis was biased towards embryonic rhabdomyosarcoma.
Family members of the children took a group photo with Dr. Akio Akimoto, head of the Proton Center of the National Cancer Center of Japan
The father of the patient soon contacted XKmed (with Kang Evergreen), contacted Ms. Bi Yanan from the International Medical Department, consulted about the itinerary to Japan and conducted a remote consultation. treatment.
It took about one month from the start of consultation to the start of treatment in Japan, including visa application. The family members of the patients took their pathological slides in China and made a pathological diagnosis again at the National Cancer Center. The result was also considered to be embryonic rhabdomyosarcoma to the greatest extent.
This little patient and his family, they obtained a medical visa on June 24, 2015, arrived in Japan on June 28, started the inspection on June 29, and completed the inspection on July 1. Professor Qiu Yuan, deputy director of the Eastern Hospital of the National Cancer Center of Japan, made a treatment plan. The treatment time is from July 14 to August 18, 2015. The total dose is: 41.4GyE, a total of 23 exposures.
On August 20, 2015, the patient’s family boarded a flight back home and successfully completed proton therapy. According to the final treatment report of the National Cancer Center, the CD of the CT before and after the patient’s irradiation has also been passed to the father of the patient.
World-Class Care at National Cancer Center East Hospital
The National Cancer Center is Japan’s most cancer treatment institution, and it is also well-known worldwide. The National Cancer Center East Hospital was established in Chiba Prefecture in 1992. Proton therapy is also one of the features here, and it has become famous because of the healing of Japanese cultural celebrities. The proton therapy system here is the first in Japan and the second medical institution in the world to begin clinical application.
Dr. Akio Akimoto, deputy director of the Eastern Hospital of the National Cancer Center and head of the radiotherapy and proton center in Japan, has extensive treatment experience as a head. By bringing Kang Evergreen to help patients who are treated in Japan, they can get the opportunity for personal treatment by Dr. Akimoto. Many Japanese cancer patients are also relatively rare.
Understanding Rhabdomyosarcoma and Long-Term Benefits of Proton Therapy
Rhabdomyosarcoma (RMS) is a malignant tumor of interstitial origin. It is the most common type of soft tissue sarcoma in children. Its incidence is inferior to malignant fibrous histiocytoma and liposarcoma.
Although the cost of using proton therapy for pediatric patients is higher than that of photon therapy, if the medical costs of treating late adverse reactions are considered in these analyses, proton therapy will ultimately save the total treatment cost because proton therapy will reduce late adverse reactions after treatment.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Sai Sree
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.